Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Receivables (2016 - 2025)

Historic Receivables for Sunshine Biopharma (SBFM) over the last 10 years, with Q3 2025 value amounting to $4.2 million.

  • Sunshine Biopharma's Receivables rose 2910.87% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 2910.87%. This contributed to the annual value of $3.9 million for FY2024, which is 5156.23% up from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Receivables is $4.2 million, which was up 2910.87% from $3.6 million recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Receivables peaked at $4.2 million during Q3 2025, and registered a low of $22.0 during Q3 2022.
  • Its 5-year average for Receivables is $2.1 million, with a median of $2.0 million in 2023.
  • Its Receivables has fluctuated over the past 5 years, first crashed by 9805.14% in 2022, then soared by 924589545.45% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Receivables (Quarter) stood at $7798.0 in 2021, then skyrocketed by 24421.07% to $1.9 million in 2022, then skyrocketed by 33.48% to $2.6 million in 2023, then skyrocketed by 51.56% to $3.9 million in 2024, then increased by 7.42% to $4.2 million in 2025.
  • Its Receivables stands at $4.2 million for Q3 2025, versus $3.6 million for Q2 2025 and $3.4 million for Q1 2025.